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Abstract 
Milk fat is high in saturated fatty acids (SFA) and high intakes of SFA are associated with cardiovascular 
diseases. The aim of the present study was to prospectively evaluate the potential risk of a first-ever 
acute myocardial infarction (AMI) in relation to the estimated milk-fat intake, reflected as the proportions 
of pentadecanoic acid (15:0) and heptadecanoic acid (17:0) in serum lipid esters. This was evaluated in a 
study population selected within the Västerbotten Intervention Program and the northern Sweden 
‘Monitoring of Trends and Determinants in Cardiovascular disease’ survey populations. A prospective 
case–control design was used. The proportions of the biomarkers were lower in the cases (n78) than in 
the controls (n156), who were matched for age, sex, sampling time and geographical region. The 
standardised odds ratios of becoming an AMI case were between 0·7 and 0·8 for the biomarkers. The 
proportions of 15:0 and 17:0 in serum phospholipids were significantly and negatively correlated to serum 
concentrations of plasminogen activator inhibitor-1, tissue-type plasminogen activator, triacylglycerols, 
insulin, specific insulin, pro-insulin and leptin (all P<0·0001), suggesting a negative relationship to the 
insulin-resistance syndrome and the risk of CHD. Adjustment for BMI did not materially change the 
relationships. Although there seems to be a negative association between milk-fat intake as mirrored by 
the proportions of 15:0 and 17:0 in serum lipid esters and a first-ever AMI, adjustment for clinical risk 
factors removed this relationship. 
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Milk fat is high in saturated fatty acids (SFA) and high intakes of SFA are associated with cardiovascular diseases. The aim of the present
study was to prospectively evaluate the potential risk of a first-ever acute myocardial infarction (AMI) in relation to the estimated milk-fat
intake, reflected as the proportions of pentadecanoic acid (15 : 0) and heptadecanoic acid (17 : 0) in serum lipid esters. This was evaluated
in a study population selected within the Västerbotten Intervention Program and the northern Sweden ‘Monitoring of Trends and Deter-
minants in Cardiovascular disease’ survey populations. A prospective case–control design was used. The proportions of the biomarkers
were lower in the cases (n 78) than in the controls (n 156), who were matched for age, sex, sampling time and geographical region. The
standardised odds ratios of becoming an AMI case were between 0·7 and 0·8 for the biomarkers. The proportions of 15 : 0 and 17 : 0 in
serum phospholipids were significantly and negatively correlated to serum concentrations of plasminogen activator inhibitor-1, tissue-type
plasminogen activator, triacylglycerols, insulin, specific insulin, pro-insulin and leptin (all P,0·0001), suggesting a negative relationship
to the insulin-resistance syndrome and the risk of CHD. Adjustment for BMI did not materially change the relationships. Although there
seems to be a negative association between milk-fat intake as mirrored by the proportions of 15 : 0 and 17 : 0 in serum lipid esters and a
first-ever AMI, adjustment for clinical risk factors removed this relationship.
Pentadecanoic acid: Heptadecanoic acid: Milk fat: Acute myocardial infarction
Atherosclerosis and its consequences are currently the
leading cause of death in the Western world (Libby,
2000). Many risk factors have been linked to the develop-
ment of atherosclerotic cardiovascular disease including
dietary fatty acid composition (Willett, 1998; Schaefer,
2002). A diet high in saturated fatty acids (SFA) and
cholesterol has long been associated with the risk of cardi-
ovascular disease (Keys et al. 1986; Ulbricht & Southgate,
1991). The main mediating factor between dietary fat con-
sumption and CHD risk is thought to be blood cholesterol
concentration, which is directly affected by the dietary
fatty acid composition. Other factors that probably link
saturated fat consumption and CHD risk are atherosclerosis
(long-term effects of diet), thrombosis (short-term effects
of diet and hormonal responses to external events)
(Ulbricht & Southgate, 1991), and insulin resistance
(Vessby, 2000). The intake of milk and other dairy pro-
ducts contributes to a large proportion of the total and satu-
rated fat intake (and of cholesterol as well), thus suggesting
a link between the risk of cardiovascular disease and the
consumption of dairy products.
It is known that the fatty acid composition in the blood
and body tissues partly reflects the fatty acid composition
of the diet at various time points after ingestion. Changes
in the composition of dietary fatty acid intake are reflected
in plasma lipids and erythrocyte membranes weeks and
months after intake respectively, while the incorporation
of fatty acids in adipose tissue reflects long-term changes
in the diet (years) (Dougherty et al. 1987; Glatz et al.
1989; Ma et al. 1995; Katan et al. 1997). It has been
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suggested that the fatty acid composition of serum lipid
esters predicts CHD. An increased risk is associated with
a higher proportion of SFA (Miettinen et al. 1982).
The fatty acids pentadecanoic acid (15 : 0) and heptade-
canoic acid (17 : 0) in adipose tissue and serum phospholi-
pids and cholesteryl esters have recently been proposed as
biomarkers of dietary ruminant fat (milk fat and fat from
ruminants; for example, beef and sheep) intake. Several
studies have verified these as relative and objective esti-
mates of milk-fat intake, both in men and women (Wolk
et al. 1998, 2001; Smedman et al. 1999) in a Western popu-
lation. Unlike ruminal microbes of dairy cattle, the human
body is unable to synthesise fatty acids with an uneven
number of C atoms (Wu & Palmquist, 1991). To measure
the serum content of 17 : 0 and/or 15 : 0 in serum lipid
esters or the corresponding proportion of triacylglycerol
fatty acid content of adipose tissue will consequently be a
way to estimate the milk-fat intake. The term ‘milk fat’
includes all fat from dairy foods such as milk, cheese, ice
cream, yoghurt and butter (Berner, 1993).
CHD mortality differences between countries were in a
meta-analysis (forty countries) explained by differences
in SFA and cholesterol intakes. Paradoxically, mortality
rates were low in France and high in Finland, although
intakes of SFA and cholesterol were comparable. It was
suggested that this difference was due to a high consump-
tion of dairy products in Finland and a high intake of plant
foods in France respectively (Artaud-Wild et al. 1993).
However, it has been difficult to demonstrate significant
relationships between the estimated intake of saturated
fat and the incidence of CHD in prospective studies
within populations (Pietinen et al. 1997). This might be
due to methodological problems; for example, day-to-day
variations in individual intake as compared with differ-
ences between individual groups. Some intervention
studies have demonstrated that dairy products may
induce hypocholesterolaemic effects in human subjects
(Eichholzer & Stähelin, 1993), and adolescents with a
high intake of dairy fat had low serum cholesterol levels
(Samuelsson et al. 2001). Also, a recent study in the
USA showed that dairy consumption was inversely related
to manifestations of the insulin-resistance syndrome among
young adults that were overweight from the beginning
(Pereira et al. 2002).
It seems relevant to question whether a high consumption
of dairy products is really harmful with respect to CHD in
general and acute myocardial infarction in particular. The
aim of the present study was to prospectively evaluate the
potential risk of a first-ever AMI in relation to the estimated
milk-fat intake, reflected as the proportions of 15 : 0 and
17 : 0 in serum lipid esters. The study was approved by the
research ethics committee at Umeå University and all par-
ticipants had given informed consent.
Methods
Study population
The study population was selected within the Västerbotten
Intervention Program and the northern Sweden Monitoring
of Trends and Determinants in Cardiovascular disease
(MONICA) survey populations, according to procedures
as described earlier (Huhtasaari et al. 1988; Weinehall
et al. 1998a,b). In the present prospective study, baseline
is the day when cases and controls had participated in
the respective health survey and had donated a blood
sample to the Northern Sweden Medical Research Bank.
Case finding
AMI events were defined according to the MONICA pro-
ject criteria (Anonymous, 1988) and incidence cases were
defined by the northern Sweden MONICA incidence regis-
try (Huhtasaari et al. 1988). At the time of definition,
30 September 1994, eighty-six cases fulfilled the following
two criteria:
(1) The cases were registered in the northern Sweden
MONICA incidence registry during the period between
1 January 1985 and 30 September 1994.
(2) The cases had participated in the health surveys
before the AMI event and at the same time had donated
a blood sample to the Northern Sweden Medical Research
Bank.
Seventy-eight cases (sixty-two men and sixteen women)
remained for analyses after the exclusion of six individuals
with cancer and two individuals without blood samples.
Two controls were randomly selected within the two
survey populations and matched for sex, age (^2 years),
type and date of health survey (^1 year) and geographical
region. Potential controls were excluded if they had died or
moved away from the area before 30 September 1994, or if
a prior AMI, stroke or cancer diagnosis could not be
excluded.
Biochemical analyses
Blood samples were collected after a minimum of 4 h fast-
ing and analysed as described previously. During the first
years of the Västerbotten Intervention Program health
survey the requested fasting period was 4 h. Since a
majority of the health surveys were performed in the morn-
ing most participants had an overnight fast. The minimum
fasting time was changed in 1992 to 8 h in the Västerbotten
Intervention Program health survey. Cholesterol (Weine-
hall et al. 1998a,b), triacylglycerols and fasting plasma
glucose were measured immediately after collection at
each study centre using capillary blood, using Reflotron
instruments (Boehringer Mannheim Scandinavia,
Bromma, Sweden). All other measurements were per-
formed on serum samples that were prepared at the most
2 h after collection and then frozen temporarily at 2208C
for up to 1 week. The samples were then transported to
the blood bank and stored at 2808C until analysed. The
different measurements were carried out at several colla-
borating laboratories as described previously (except for
fatty acid composition) (Thörgersen et al. 1998; Lindahl
et al. 1999; Söderberg et al. 1999).
Fatty acid composition of serum lipid esters
The fatty acid analyses were performed at the clinical
research laboratory at the Department of Public Health
and Caring Sciences at Uppsala University. The fatty acid
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composition of the serum lipids was analysed by means of
GLC, as described in detail elsewhere (Boberg et al. 1985).
Briefly, the serum lipids were extracted in chloroform, sep-
arated by TLC, transmethylated and separated by GLC on a
capillary column. The analyses were carried out on a GC
5890, equipped with a 7671A auto-injector, a 3392A inte-
grator (all from Hewlett-Packard, Avondale, PA, USA)
and a 25 m Nordion fused silica column NS-351 (HNU Sys-
tems Inc., Helsinki, Finland), using He as the carrier gas.
The temperature was programmed to 100–2108C. The
fatty acids were identified by comparing each peak’s reten-
tion time with those of methyl ester standards (GLC- 68A;
Nu Check Prep, Elysian, MN, USA). The relative amount
of each fatty acid (percentage of total fatty acids) was quan-
tified by integrating the area under the peak and dividing the
results by the total area for all fatty acids. The CV for the
analyses were ,10% for all fatty acids in both phospholi-
pids and cholesteryl esters, except for 15 : 0 in cholesteryl
esters with a CV of 13·4%.
Biomedical analyses
Blood pressures were recorded after 5 min of rest in a sit-
ting or recumbent position (adjusted for sitting posture)
using an Hg sphygmomanometer. The diastolic blood
pressure was defined as Korotkoff’s 5th phase. Hyperten-
sion was defined as systolic blood pressure $160 mmHg
and/or diastolic blood pressure $95 mmHg or if the patient
was on anti-hypertensive medication during a period of 14 d
before the health survey. Smokers were divided into daily
smokers and non-smokers. Smokers were those reporting
a daily consumption of cigarettes, cigarillos, cigars or
pipe tobacco. Individuals reporting occasional smoking or
being an ex-smoker were included in the non-smokers
group. History of diabetes was obtained from self-reported
questionnaires. Weight was measured without shoes in light
clothing to the nearest 0·2 kg and height to the nearest
10 mm, without shoes. BMI was calculated as body
weight (kg) divided by height (m2) (Thörgersen et al.
1998; Lindahl et al. 1999; Söderberg et al. 1999).
Statistical analyses
The statistical analyses were performed using the software
packages STATA (version 6.0; STATA Corp., College
Station, TX, USA), JMP (version 3.1; SAS Institute Inc.,
Cary, NC, USA) and SAS (version 6.12; SAS Institute
Inc.) on a personal computer. The normal distribution of the
continuous variables was examined with Shapiro–Wilk’s
test. Variables not normally distributed (W , 0·95) were
log-transformed. The continuous variables were standar-
dised and used in the conditional logistic regression analyses.
Clinical risk profile and biomarkers
For each clinical variable the risk of developing a first-
ever AMI was estimated as the standardised odds ratio
(OR) by using univariate conditional logistic regression
analysis. The clinical variables were BMI, systolic blood
pressure, diastolic blood pressure, von Willebrandt
factor, plasminogen activator inhibitor (PAI)-1 antigen
(ag), Apo A-1, Apo B, triacylglycerols, cholesterol,
tissue-type (t-) PA-ag, insulin, pro-insulin, specific insulin,
leptin, plasma glucose, history of smoking, diabetes and
hypertension. The same analyses were performed with
15 : 0 and 17 : 0 as predictor variables.
Correlations between risk profile for developing acute
myocardial infarction and estimated milk-fat intake
Correlations between the proportions of 15 : 0 and 17 : 0,
and their sum in serum phospholipids and clinical study
variables, were explored with Pearson’s rank correlation.
The test was performed with and without adjustment for
BMI. Further adjustment with BMI in combination with
smoking history was made, as well. The proportions of bio-
markers in serum phospholipids were used in the analysis
since the predictor values were stronger than for those of
the biomarkers in cholesteryl esters.
Effect of biomarkers of milk-fat intake on the risk of
developing acute myocardial infarction, when adjusted for
clinical risk variables
To calculate the OR of a first-ever AMI in relation to the
proportions of 15 : 0, 17 : 0 and their sum in serum phospho-
lipids, bivariate and multivariate logistic regression ana-
lyses were used. Adjustment with all clinical variables (as
defined previously) taken together in a multivariate analysis
was first made. Bivariate logistic regression analyses were
then performed to establish OR for 15 : 0, 17 : 0, and
15 : 0þ17 : 0 in serum phospholipids to predict a first-ever
AMI, after adjustment with specific clinical variables.
Finally the logistic regression analyses were performed
when adjusted for two different groups of CHD risk factors.
The two groups were defined by us as ‘classical’ risk factors
(cholesterol, blood pressures and smoking habits) and
‘metabolic’ risk factors (triacylglycerols, insulin, pro-insu-
lin, t-PA, PAI-1, leptin and von Willebrandt factor).
The linearity assumption of the logistic regression
models was checked by comparing the above-mentioned
models to models where the biomarker (15 : 0 þ 17 : 0 in
serum phospholipids) with the strongest predictor value
was dichotomised. This showed an attenuation of the
relationships to AMI. This finding indicates that the
relationship is approximately linear. All tests were two-
tailed and P values ,0·05 were considered significant.
Results
All seventy-eight cases (sixteen women and sixty-two
men) and 156 control subjects (thirty-two women and
124 men) in the present study had participated in health
surveys before the onset of their first AMI. The mean
time between health survey and onset of disease was 18
months (median 15 months) (Weinehall et al. 1998a,b).
Clinical risk profile
The clinical characteristics of case and control groups at
baseline are presented in Table 1. Any differences between
case and control subjects are presented as standardised OR
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calculated for each individual clinical variable. When sub-
jects with missing values of any of the variables (except
triacylglycerols) were excluded, the analyses rendered
values (data not shown) that were only slightly different
from the OR shown in Table 1.
Biomarker composition of serum lipids
The proportions of the biomarkers 15 : 0 and 17 : 0 in serum
lipid esters for cases and controls were as shown in Table 2.
The means of the proportions were found to be slightly
lower in the case group. However, significant differences
in means based on univariate OR were observed only in a
few cases as described in Table 2. The OR for each
standard deviation increase of the biomarkers, in serum
phospholipids and cholesteryl esters, were calculated
separately for each fatty acid with data from all individuals.
If subjects with the missing values of any of the variables
(except triacylglycerols) were excluded in a repeated anal-
ysis, OR were in the same range, but the significance atte-
nuated for most variables and disappeared in a few cases.
The proportions of other analysed fatty acids in serum
lipids differed between cases and controls for EPA
(20 : 5n-3) and docosapentaenoic acid (22 : 5n-3). These
were significantly higher for the control subjects than the
case subjects. In order to determine if the associations
between serum biomarkers and the risk of a first-ever
AMI were mediated by the simultaneous high proportions
of EPA and docosapentaenoic acid, adjusted OR were
determined. The relationship did not change much, thus
indicating that high proportions of marine fatty acids such
as EPA and docosapentaenoic acid did not mediate the
observed effects of the proportions of 15 : 0 and 17 : 0 in
serum phospholipids.
Table 2. Proportions of pentadecanoic acid (15 : 0) and heptadecanoic acid (17 : 0) (%) and the relative risk, for
each standard deviation increase of the biomarkers in serum cholesteryl esters and phospholipids, calculated as
the odds ratio of developing a first-ever acute myocardial infarction*
(Mean values and standard deviations)
Cases Controls Relative risk
Lipid n Mean SD n Mean SD OR 95 % CI P
Cholesteryl ester
15 : 0† 67 0·21 0·045 141 0·22 0·053 0·79 0·59, 1·07 NS
17 : 0† 64 0·11 0·025 128 0·12 0·025 0·77 0·57, 1·04 NS
15 : 0þ17 : 0† 64 0·33 0·058 128 0·35 0·067 0·75 0·55, 1·00 0·053
Phospholipid
15 : 0† 62 0·21 0·04 132 0·22 0·049 0·72 0·53, 0·98 0·036
17 : 0 68 0·42 0·06 141 0·44 0·071 0·75 0·57, 1·00 0·047
15 : 0 þ 17 : 0† 62 0·63 0·094 132 0·67 0·11 0·79 0·65, 0·96 0·020
OR, odds ratio of standardised variables.
* For details of subjects and procedures, see Table 1 and p. 636.
† Log-transformed values.
Table 1. Clinical baseline characteristics
(Mean values and standard deviations)
Cases Controls Difference
Variable n Mean SD n Mean SD OR P
Age (years) 77 54·8 7·2 156 54·6 7·2
BMI (kg/m2)* 72 27·5 4·3 156 25·6 3·7 1·64 0·001
Triacylglycerols (mmol/l) 50 2·64 2·70 102 1·71 1·20 1·66 0·010
Cholesterol (mmol/l)* 76 6·80 1·40 156 6·40 1·20 1·26 0·13
Apo A-1 (g/l) 75 1·06 0·17 152 1·15 0·17 0·60 0·001
Apo B (g/l) 75 1·21 0·27 152 1·10 0·27 1·43 0·014
Insulin (pmol/l) 76 73·2 119·9 153 49·8 52·8 1·36 0·036
Pro-insulin (pmol/l) 75 17·6 34·2 153 10·8 20·0 1·43 0·013
Specific insulin (pmol/l)* 75 54·0 67·0 153 37·6 74·2 1·44 0·022
Plasma glucose (fasting) (mmol/l) 58 5·04 0·67 117 5·07 0·62 1·08 0·670
Leptin (ng/ml) 70 10·5 10·4 143 6·87 6·20 1·60 0·000
PAI-1-ag (ml/l) 76 15·6 14·0 155 11·2 9·1 1·38 0·086
t-PA-ag (ml/l)* 75 12·5 5·60 156 9·10 4·0 2·15 0·000
Systolic blood pressure (mmHg) 73 143·2 22·4 156 136·6 19·5 1·41 0·018
Diastolic blood pressure (mmHg) 73 87·7 11·0 156 84·2 10·5 1·36 0·018
vWF (% of normal)* 74 146·6 47·9 150 131·8 45·8 1·43 0·003
Number of smokers 67 29 148 41 1·94 0·023
Number of subjects with diabetes 76 6 156 1 1·76 0·068
Number of subjects with hypertension 76 31 156 43 2·32 0·001
OR, univariate odds ratio; PAI-1-ag, plasminogen activator inhibitor-1 antigen; t-PA-ag, tissue-type plasminogen activator antigen; vWF, von Willebrandt factor.
* Tests based on log-transformed values.
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Correlations between risk profile for developing acute
myocardial infarction and estimated milk-fat intake
The correlations between the proportions of 15 : 0 þ 17 : 0
in serum phospholipids and clinical variables were gener-
ally negative and are presented in Table 3. The significant
correlations remained, but were somewhat weakened after
adjustment with BMI for all variables, except for the von
Willebrandt factor where the significance disappeared.
Further adjustment with BMI in combination with smoking
habits did not change the correlation coefficients much, but
attenuated the statistical significance in most cases (data
not shown).
Effect of biomarkers of milk-fat intake on the risk of
developing acute myocardial infarction, when adjusted for
clinical risk variables
Adjustment with all clinical risk factors (both ‘classical’
and ‘metabolic’) taken together in a multivariate analysis
removed the significant effect of the fatty acids to predict
a first-ever AMI (data not shown). The results from the
bivariate regression analyses, taking specific risk factors
into account, followed the pattern from the multivariate
analyses with the two risk-factor groups, as will be dis-
cussed. The ‘classical’ risk factors, one by one, did not
change the relationship much, but each individual ‘meta-
bolic’ risk factor removed any effect (data not shown).
The results after the two multivariate regression analyses
when adjusted for the two CHD risk-factor groups were
as shown in Table 4. Only data from the analyses with
the biomarker with the strongest predictor value,
15 : 0 þ 17 : 0 in serum phospholipids, are shown. Adjust-
ment for cholesterol, blood pressures and smoking habits
removed the statistical significance, which might be
explained by the smaller number of subjects in the analysis
due to missing data. However, there was virtually no
change of the OR to predict a first-ever AMI (OR 0·82 v.
0·83). Adjustment for ‘metabolic’ risk factors removed
any relationship (OR $1·0).
Discussion
The findings in the present prospective case–control study,
in which the AMI cases were defined within two health
survey populations, suggest that a higher intake of fat
from dairy products, as estimated from the proportions of
Table 4. Univariate and multivariate conditional logistic regression: effect of pentadecanoic acid (15 : 0) þ
heptadecanoic acid (17 : 0)* in serum phospholipids on acute myocardial infarction, before and after adjustment
for ‘classical’ and ‘metabolic’ risk factors
Covariate* OR P value 95 % CI No. of observations
None 0·79 0·020 0·65, 0·96 195
None† 0·82 0·040 0·67, 0·99 178
Classical risk factors‡ 0·83 0·087 0·67, 1·03 168
Metabolic risk factors§ 1·038 0·826 0·74, 1·46 114
* Standardised variables.
† Subjects with missing values of triacylglycerols excluded.
‡ Classical risk factors are cholesterol, smoking habits, systolic blood pressure and diastolic blood pressure.
§ Metabolic risk factors are triacylglycerols, specific insulin, insulin, pro-insulin, BMI, leptin, plasminogen activator inhibitor-1,
tissue-type plasminogen activator and von Willebrandt factor.
Table 3. Pearson correlation coefficients (r) between the sum of pentadecanoic acid (15 : 0) and heptadecanoic acid
(17 : 0) in serum phospholipids and clinical variables, with and without adjustment for body mass index
Phospholipid
15 : 0 þ 17 : 0* 15 : 0 þ 17 : 0* (BMI adjusted)
Clinical variable r P r P
Triacylglycerols* 20·40 ,0·0001 20·30 ,0·001
Cholesterol 20·16 ,0·05 20·15 ,0·05
Apo A-1 0·04 NS 20·04 NS
Apo B 20·07 NS 20·04 NS
Insulin* 20·42 ,0·0001 20·27 ,0·001
Pro-insulin* 20·40 ,0·0001 20·27 ,0·001
Specific insulin* 20·36 ,0·0001 20·21 ,0·001
Leptin* 20·36 ,0·0001 20·20 ,0·05
PAI-1-ag* 20·48 ,0·0001 20·36 ,0·0001
t-PA-ag* 20·40 ,0·0001 20·27 ,0·001
Systolic blood pressure 20·08 NS 0·001 NS
Diastolic blood pressure 20·06 NS 0·031 NS
vWF* 20·18 ,0·05 20·12 NS
BMI 20·35 ,0·0001
* Based on log-transformed values.
PAI-1-ag, plasminogen activator inhibitor-1 antigen; t-PA-ag, tissue-type plasminogen activator antigen; vWF, von Willebrandt factor.
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15 : 0 and 17 : 0 and their sum (15 : 0 þ 17 : 0) in serum
phospholipids (and cholesteryl esters), seems to be associ-
ated with a reduced, rather than an increased, risk of
developing AMI.
The study population consisted of both men and women.
We know that there might be cardiovascular risk-factor
differences between men and women (Brochier & Arwid-
son, 1998). However, repeating the same analyses on a
group consisting of only the men gave only slightly differ-
ent results, compared with the entire study population.
Given this, data from the analyses including both men
and women are shown and discussed in the present
paper. The conditional logistic regression analyses were
carried out on the subgroup of individuals (212 subjects)
without any missing values of all variables, except the tria-
cylglycerols. Excluding individuals with missing triacyl-
glycerols values would have reduced the already low
number of individuals in the analyses to 139. The concen-
tration of triacylglycerols is an important marker of insulin
resistance and thereby also an important factor in the
development of cardiovascular disease, but insulin resist-
ance is related to a clustering of risk factors (Gensini
et al. 1998), many of which were included in the analyses.
Thus including some individuals with missing triacylgly-
cerols values in our analyses anyway will probably not
influence the outcome of the study.
The observed differences in clinical characteristics
between the case and control groups at baseline were as
expected, with a higher mean BMI and an increased fre-
quency of lipid disorders and other metabolic abnormalities
among the cases. The number of subjects with high blood
pressures, diabetes and the reported number of smokers
were greater among the cases than among the controls
(Thörgersen et al. 1998; Lindahl et al. 1999; Söderberg
et al. 1999). The case subjects had slightly lower pro-
portions of 15 : 0 and 17 : 0 in the blood lipids, than did
the control subjects. This suggests that a higher estimated
consumption of dairy products does not predict a first-
ever AMI. Our analyses also rendered OR between 0·7
and 0·8 for the biomarkers, which suggests a 20–30%
decreased risk of AMI after each standard deviation
increase of the proportion of biomarkers, measured in
blood serum phospholipids. The negative associations
found between the proportions of biomarkers and the mag-
nitude of other CHD risk factors might indicate that those
with a high intake of dairy fat have a reduced rather than
an increased associated risk. The factors found to most
strongly confound the effect of milk-fat biomarkers on
AMI (Table 4) were the risk factors defined by us as ‘meta-
bolic’, such as PAI-1-ag, t-PA-ag, leptin and triacylglycer-
ols, all closely associated with the metabolic impairment
characteristic of the insulin-resistance syndrome (Haffner,
1996; Juhan-Vague et al. 1996). The ‘classical’ CHD fac-
tors did, however, not remove the effect of milk fat to pre-
dict a first-ever AMI, as the OR remained virtually
unchanged. This observation might suggest that the posi-
tive effects of milk fat on the risk of AMI is separate
from the effects of the ‘classical’ CHD risk factors, but
correlated to ‘metabolic’ risk factors. We observed in the
logistic regression model that the effect of the estimated
intake of milk fat on AMI is removed, when adjusted for
other ‘metabolic’ risk factors (Table 4). It is conceivable
that high proportions of milk fat in the food, as reflected
by the proportions of 15 : 0 and 17 : 0 in the blood, could
affect the incidence of AMI through the effects on ‘meta-
bolic’ risk factors. However, based on these results we
can say nothing about the causality of the relationship.
We can say, however, that the relationship between milk
fat and AMI is not directly related to and not mediated
by ‘classical’ risk factors in the subjects in the present
study. Another possible explanation is that a high con-
sumption of dairy fat is part of a ‘healthy food pattern’,
thus reducing the risk of CHD and AMI.
The proportions of 15 : 0 and 17 : 0 in serum lipids and in
adipose tissue triacylglycerols have in several studies been
shown to be valid markers for dairy-fat intake (Wolk et al.
1998, 2001; Smedman et al. 1999). Accounting for the esti-
mated intake of the same fatty acids in ruminant meat does
not affect the relationships significantly (Wolk et al. 1998,
2001). A small proportion of 15 : 0 and 17 : 0 is also found
in fat from fish but the absolute dietary intake is almost
negligible, considering the low daily intake of fat from
fish compared with that from dairy fat. The inverse
relationship between the proportions of 15 : 0 and 17 : 0
in serum phospholipids and AMI in the present study is
not confounded by the intake of fat from fish. The relation-
ships were unchanged when adjusted for the proportions of
EPA and docosahexaenoic acid, which are known to be
valid markers for dietary intake of fat from fish.
Biomarkers and risk factors in the development of acute
myocardial infarction
The significant and negative correlations we found between
clinical variables and biomarkers in serum phospholipids
confirm and extend previous findings among elderly men
(Smedman et al. 1999). In that study, negative associations
were found between biomarkers and body weight, BMI,
Apo B, hip circumference and waist circumference,
whereas positive correlations were found for Apo A-1
and HDL-cholesterol (Smedman et al. 1999). In a recent
case-control study from Norway (Yli-Jama et al. 2002),
patients with a first myocardial infarction were compared
with population controls with regard to the pattern of
serum non-esterified fatty acids. There was a decreasing
risk of myocardial infarction with increasing quartiles of
myristic acid (14 : 0), which is also a marker of milk-fat
intake. Also the proportions of long-chain n-3 fatty acids,
as well as of stearic acid (18 : 0), were found to be inver-
sely related to the risk for myocardial infarction.
Milk and milk products as markers of a ‘healthy food
pattern’?
It is possible that a high intake of dairy products in the pre-
sent study population is part of a ‘healthy food pattern’; for
example, a high consumption of fruits and vegetables. Such
a diet is high in dietary fibre, vitamins and minerals. It is
widely recognised that soluble dietary fibres favourably
reduce cholesterol levels by yet unknown mechanisms.
Dietary fibre may also change serum levels of certain hor-
mones involved in lipid metabolism, thus affecting the
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development of CHD (van Horn, 1997). If the associations
between milk-fat biomarkers and the development of AMI
were a result of a ‘healthy food pattern’ we could expect
the associations to disappear after adjustment for intakes
of fruits, vegetables and wholegrain cereals. This adjust-
ment was not done in the present study but was performed
in another study, where negative correlations between
15 : 0 in serum cholesteryl esters and metabolic variables
were observed in young adolescents in Sweden. The
adjustment had only a minor effect on the correlations
(Samuelsson et al. 2001), indicating that fruit and veg-
etables (independent of energy intake) did not mediate
the beneficial effects of the estimated intake of milk fat
in that study. This is also supported by Smedman et al.
(1999), where the negative associations observed between
clinical variables and 15 : 0 in serum lipid esters remained,
although in most cases weakened, after adjustment for, for
example, potatoes, beet crops and vegetables. This is
further supported by the study by Pereira et al. (2002).
They found that the inverse correlation between dairy
intake and the insulin-resistance syndrome was not con-
founded by dietary fibre intake (Pereira et al. 2002).
‘Metabolic’ risk factors and milk fat
‘Metabolic’ risk factors, such as PAI-ag, t-PA-ag, triacyl-
glycerols, insulin, pro-insulin, specific insulin and leptin
were all negatively correlated to the estimated milk-fat
intake in the present study population. These variables
are linked to the development of CHD and atherothrombo-
tic disease (Gensini et al. 1998; Thörgersen et al. 1998;
Lindahl et al. 1999; Söderberg et al. 1999). The clustering
of risk factors increases the risk of CHD and is associated
with insulin resistance (Solomon & Manson, 1997; Gensini
et al. 1998). An increased proportion of SFA in the diet
impairs insulin sensitivity (Vessby et al. 2001). It is thus
easy to believe that a diet rich in milk fat, and therefore
high in SFA, would predict a first-ever AMI, but the
results of the present study indicate the opposite. Many
of the variables found to be negatively correlated to the
estimated intake of milk fat are linked to obesity and
insulin resistance. It is interesting that many of the negative
associations between dairy-fat intake and ‘metabolic’
risk factors remained after adjustment for BMI, which
might indicate that these associations are related to
regional adiposity (central obesity), often consistent with
the insulin-resistance syndrome, rather than to overweight
as such (Haffner, 1996). Impaired fibrinolysis is also a
common feature of the insulin-resistance syndrome and
several thrombotic diseases such as AMI. PAI-1 has been
found to be associated with many metabolic risk factors
that may affect the risk of CHD such as BMI, central
body fat and serum triacylglycerols and has been suggested
to be a possible link between insulin resistance and CHD
(Haffner, 1996). Mennen et al. (1999) found t-PA-ag to
be inversely correlated with the intake of milk, milk pro-
ducts and cheese, independently of each other. These
associations remained after adjustment for smoking, BMI,
blood pressure and total cholesterol. They concluded that
a high intake of dairy products may enhance fibrinolysis
(Mennen et al. 1999).
Conclusion
Although there seems to be a negative association between
a high milk-fat intake mirrored by the proportions of 15 : 0
and 17 : 0 in serum lipid esters, and a first-ever AMI,
adjustment for clinical risk factors removed this relation-
ship. We can speculate about possible mechanisms
behind these findings, but it is not possible to draw any
conclusions about causality. Further studies are needed to
elucidate the mechanisms behind these relationships and
to verify the findings of the present study.
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